

(51) International Patent Classification <sup>6</sup> :  A61K 31/59	A1	(11) International Publication Number: <b>WO 98/56387</b>  (43) International Publication Date: 17 December 1998 (17.12.98)
<p>(21) International Application Number: PCT/AU98/00440            (22) International Filing Date: 10 June 1998 (10.06.98)              (30) Priority Data:            PO 7270                    10 June 1997 (10.06.97)                    AU</p> <p>(71) Applicant (<i>for all designated States except US</i>): UNISEARCH LIMITED [AU/AU]; 221-227 Anzac Parade, Kensington, NSW 2033 (AU).              (72) Inventor; and            (75) Inventor/Applicant (<i>for US only</i>): MORRIS, David, Lawson [GB/AU]; 960 Forest Road, Lugarno, NSW 2210 (AU).              (74) Agent: F. B. RICE &amp; CO.; 605 Darling Street, Balmain, NSW 2041 (AU).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b>  <i>With international search report.</i></p>
<p><b>(54) Title:</b> METHOD OF TREATMENT OF LIVER TUMOURS AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN</p> <p><b>(57) Abstract</b></p> <p>The present invention is concerned with a method for the treatment of tumours in the liver of a subject. The method involves regional delivery of a vitamin D compound to the liver, for example, by intraarterial infusion to the hepatic artery. The invention is also concerned with compositions suitable for such treatment.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon			PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

***Method of treatment of liver tumours and pharmaceutical compositions  
for use therein***

The present invention is concerned with a method for the treatment of  
5 tumours and in particular, with a method for the treatment of tumours in the  
liver. The invention is also concerned with compositions suitable for such  
treatment.

Hepatoma (primary liver cancer) is one of the commonest causes of  
cancer death in the world with an estimated incidence of 1 million cases per  
10 year worldwide (Lencioni R and Bartolozzi C, The Cancer Journal, Vol 10,  
pp1-6). There is a considerable variation in its incidence with it being the  
most common in Asian countries, although it is now of increasing  
importance in the West. There are currently few effective treatment options  
available. Untreated, the average survival in this condition is of the order of  
15 3 months. Liver resection may allow 5 year survival in approximately 40% of  
cases but very few patients are eligible for such treatment. Systemic  
chemotherapy has been of very limited value in the treatment of primary  
hepatic cancer, and attempts have consequently been made to deliver  
pharmacologically active agents directly to the liver using the technique of  
20 transarterial chemoembolisation (TAE). TAE combines the selective delivery  
of agents to hepatic tumours vascularized by the hepatic artery and thus their  
concentration in the tumour, with the concept of causing embolisation of the  
tumour and hence necrosis by ischemia. A wide range of chemotherapy  
agents have been delivered in this way, including doxorubicin, epirubicin  
25 and cisplatin (Choi, J. Cancer Control, Vol 3, pp407-413, 1996). Frequently,  
chemotherapeutic agents are emulsified with or dissolved in the contrast  
agent Lipiodol, which is an iodised poppy seed oil fatty acid ethylester.  
Uptake of iodised oil into tumours is thought to prolong contact of the  
30 chemotherapeutic agent with tumour, and the radioopaque nature of the  
medium enables progress of the infusion to be monitored by radiography.

Vitamin D is an isoprenoid compound made up of activated 5-carbon units. The most abundant form of vitamin D is vitamin D<sub>3</sub>, or cholecalciferol. Vitamin D<sub>3</sub> arises from biosynthesis of 7-dehydrocholesterol, an intermediate in cholesterol biosynthesis. Vitamin D<sub>3</sub> is metabolised in the liver to 25-hydroxycholecalciferol [25(OH)D<sub>3</sub>] which is a major form of Vitamin D circulating in the blood compartment. 25(OH)D<sub>3</sub> is converted by the kidney to produce two principal dihydroxylated metabolites, namely, 1,25-dihydroxycholecalciferol [1,25(OH)<sub>2</sub>D<sub>3</sub>] and 24,25-dihydroxycholecalciferol [24R,25(OH)<sub>2</sub>D<sub>3</sub>].

10 1,25(OH)<sub>2</sub>D<sub>3</sub> is the most biologically active naturally occurring form of vitamin D<sub>3</sub> and is transported in the bloodstream to its major site of action in the mucosal cells of the intestine, where calcium absorption is stimulated. Thus vitamin D<sub>3</sub> may be regarded as a prohormone because it is converted to a metabolite that acts analogously to a steroid hormone. It regulates calcium 15 and phosphorous metabolism particularly in the synthesis of the inorganic matrix of bones.

20 Therapeutically, 1,25(OH)<sub>2</sub>D<sub>3</sub> and certain other analogues of Vitamin D<sub>3</sub> are used to counteract deleterious effects of dietary deficiency of Vitamin D (rickets), or in the treatment of diseases characterised by abnormalities in the synthesis of or response to Vitamin D such as hypophosphatemic vitamin D-resistant rickets and renal osteodystrophy (renal rickets). A further use in the calcification-related disease osteoporosis is distinct from assuring 25 vitamin D nutritional adequacy. Here, the rationale is directly to suppress parathyroid function and reduce bone turnover (Goodman & Gilman, The Pharmacological basis of Therapeutics. Pub. 1992, The McGraw Hill Companies Inc). Finally, a recent use of Vitamin D<sub>3</sub> analogues is in the treatment of the cutaneous disease psoriasis.

30 Experimental studies have shown that Vitamin D<sub>3</sub> receptors are present on a range of cell types and so the understanding has arisen that the Vitamin D endocrine system is involved in the modulation of a number of

fundamental cellular processes not directly related to calcium homeostasis (Pols, HAP et al, J Steroid Biochemistry, Vol 37, pp873-876, 1990). Included amongst the cells bearing Vitamin D<sub>3</sub> receptors are a number of malignant tissues or cell lines derived from tumours. The presence of receptors on some 5 cancer cells has been shown to have a functional significance in a number of cases, and the literature contains reports of Vitamin D<sub>3</sub> and analogues being able to inhibit the proliferation of melanoma, osteosarcoma and breast carcinoma cells (Deluca HF and Ostrem V, Advances in Experimental Medicine and Biology, Vol 206, pp413-429, 1986) colon adenocarcinoma cells 10 (Cross HS et al Journal of Nutrition, Vol 127 Suppl. pp2004-2008, 1995) and hepatic tumour cells (Tanaka Y et al, Biochem Pharmacol vol 38 pp449-453, 1989).

This effect in vitro has given rise to the hope that Vitamin D<sub>3</sub> and analogues could be used in the treatment of cancers. Vitamin D<sub>3</sub> compounds 15 are listed among "unconventional cancer therapies" (British Columbia Cancer Agency publication; 600 West 10th Ave, Vancouver, BC, Canada), and clinical trials have attempted to show an effect. Unfortunately, attempts to use naturally occurring analogues of Vitamin D<sub>3</sub> such as 1,25(OH)<sub>2</sub> D<sub>3</sub> have not been associated with the successful treatment of cancer and indeed have 20 rarely been attempted. This is due in large part to the observation that for growth reduction of cancer cells to be caused by Vitamin D<sub>3</sub>, supraphysiological concentrations are needed (Pols et al - ibid). The consequence of this is that before anti-tumour properties of the treatment can 25 be expressed, the effects of Vitamin D<sub>3</sub> on calcium homeostasis are expressed to an excessive and dangerous degree, leading to life-threatening toxicity from hypercalcaemia.

In an attempt to overcome this problem, and to disassociate the 30 hypercalcaemic effect of Vitamin D<sub>3</sub> from its actions on cell differentiation, the pharmaceutical industry has expended much effort on the search for synthetic analogues that are devoid of an effect on calcium metabolism, and

might therefore be useful for the treatment of cancer or other diseases. This approach has met with some limited success. For example, the analogue Calcipotriol has been synthesized which contains a 22-23 double bond, a 24(S)-hydroxy functional group, and carbons 25-27 incorporated into a cyclopropane ring. This compound has receptor affinity similar to that of 1,25(OH)<sub>2</sub> D<sub>3</sub>, but it is less than 1% as active as 1,25(OH)<sub>2</sub> D<sub>3</sub> in regulating calcium metabolism. Calcipotriol has been studied extensively as a potential treatment for psoriasis (Goodman & Gilman, The Pharmacological Basis of Therapeutics Pub McGraw Hill, 1992). However, despite its reduced effect on calcium metabolism, calcitriol is used topically in order to avoid systemic hypercalcaemia. Examples have also been disclosed of synthetic Vitamin D analogues claimed to be useful for the treatment of tumours which have reduced effects on calcium metabolism (United States patent 4,891,364, Jan 2 1990). Also, attempts have been made to treat certain cancers locally. Thus, Bower M *et al* treated breast cancer topically with Calcipotriol (Lancet vol 337: No 8743 pp701-702). Of the 19 patients treated, only 3 showed a significant response and 1 a minimal response. Moreover, even though this synthetic analogue has a drastically reduced effect on calcium metabolism (*vide supra*) and even though the treatment was locally restricted to skin around breast cancer lesions, still 2 of the 19 patients became hypercalcaemic during treatment.

Thus, despite the interesting findings of basic researchers and the intensive efforts of the pharmaceutical industry, the application of Vitamin D compounds to cancer therapy has not been successful. The key limitation has been either an inherent lack of activity, or the low therapeutic index (ratio of effective dose to toxic dose) of Vitamin D<sub>3</sub> which has made its use so difficult.

We have found that, surprisingly, regional delivery to the liver of a vitamin D compound, such as vitamin D<sub>3</sub> or a precursor, metabolite or analogue thereof, avoids the production of hypercalcaemia, even at high

doses of the vitamin D compound. For example, despite the fact that therapeutic oral and intravenous doses of 1,25(OH)<sub>2</sub> D<sub>3</sub> are typically in the order of 0.5 to 3 mcg/day (at or beyond which level there is a distinct risk of hypercalcaemia developing), we have shown (Example 2) that doses of at least 10mcg/day can be administered intraarterially to the liver without any observable systemic toxicity.

A reasonable conclusion of this observation is that the avoidance of hypercalcaemia after such high doses of Vitamin D compound is due to increased retention of the Vitamin D compound in the liver, or degradation in the liver (a first pass effect). However, neither of these occurrences could have been predicted for the following reasons: The dose provided is much higher than physiological levels, and thus, although arterial infusion would bring the Vitamin D compound into contact with cells bearing Vitamin D receptors, they would not be expected to be capable of trapping all the Vitamin D compound. Concerning degradation, the major metabolic activity of the liver is applied to compounds entering via the hepatic portal route, not the hepatic artery. Moreover, as was discussed above, the liver is one of the sites of activation of Vitamin D and would not necessarily be expected to remove Vitamin D compounds from the blood. The precise reasons why the Vitamin D compound induce less hypercalcaemia after hepatic arterial delivery are not known.

Regional delivery of Vitamin D<sub>3</sub> to the liver has not only been shown to be safe, but in 4 of 7 patients had at least a limited response to treatment as indicated by changes in their rate of rise of tumour marker.

Thus, not only has the surprising ability to administer large doses of Vitamin D compound to the liver by regional delivery been demonstrated, but also indications of a beneficial effect on disease progress have been obtained.

Accordingly, the first aspect of the present invention consists in a method of treating a tumour in the liver of a subject including administering

to the subject a pharmaceutically effective amount of at least one vitamin D compound selected from the group consisting of vitamin D, a precursor of vitamin D, or a metabolite or analogue thereof, wherein the vitamin D compound is regionally delivered to the liver.

5       The regional delivery of the vitamin D compound may be achieved by intraarterial delivery or delivery via the portal vein. Preferably the vitamin D compound is delivered intraarterially. Particularly preferred is where the vitamin D compound is delivered by intraarterial infusion via the hepatic artery.

10      The method of treatment of the invention may be used to treat primary or secondary cancers of the liver. The method of the invention is particularly suitable for the treatment of hepatoma (primary liver cancer) in a subject. The method of the invention may also be used to treat secondary cancers in the form of metastases in the liver, for example, metastases of colorectal 15     cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer or renal cancer. The secondary cancer may be a sarcoma. The method of the invention may be used to treat primary or secondary liver cancers in the liver.

20      Preferably the vitamin D compound is vitamin D<sub>3</sub> or a precursor or metabolite thereof, although the vitamin D compound may be an analogue of vitamin D<sub>3</sub>.

25      The vitamin D analogue compound may be selected from any suitable analogue, for example, 1,25 (OH)<sub>2</sub> D<sub>3</sub> (1,25-dihydroxycholecalciferol), OCT (22-Oxacalcitriol), MC903 (calcipotriol) or EB1089 (1  $\alpha$ ,25 (OH)<sub>2</sub> 22,24 diene 24,26,27 trihomo D<sub>3</sub>).

30      The metabolite of vitamin D may be a hydroxylated or other product of vitamin D or its analogues.

35      The effect of the vitamin D compound on tumours is very dose dependent and there is therefore advantage in delivering high concentrations of the vitamin D compound to the tumour. However, the limited solubility of

vitamin D compounds in a conventional carrier such as aqueous media places an upper limit on the amount of compound that can be delivered to the tumour.

We have found that very high concentrations of a vitamin D compound, such as  $1,25(\text{OH})_2\text{D}_3$ , can be achieved by dissolving the compound in a pharmaceutically acceptable oil. For example, 2mg of  $1,25(\text{OH})_2\text{D}_3$  can be readily dissolved in 1 ml lipiodol. This high solubility allows for very high concentrations of vitamin D compound to the tumour. A further advantage of using an oil as the carrier for the vitamin D compound is that some oils are concentrated in certain tumours allowing the achievement of very high tumour concentrations of the vitamin D compound. Moreover, another advantage of achievement of high concentrations is that some vitamin D compounds that are inactive at low concentrations may become active at the much higher concentrations achieved when an oil is used to dissolve the compound.

Accordingly, in a second aspect the present invention consists in a method of treatment of the first aspect wherein the vitamin D is delivered as a solution of the vitamin D compound in a pharmaceutically acceptable oil.

The oil may be an iodised oil such as lipiodol although clearly the presence of iodine, while possibly being useful to allow infusion to be monitored radiographically, is not an essential feature of the oily agent. Furthermore, the oily agent needs only to (1) incorporate large amounts of Vitamin D compound and (2), if possible, be taken up into tumours being treated. Therefore, to one skilled in the art, the carrier could also be deemed to include other oils and chemically modified oils used in the pharmaceutical industry such as Cremophor (polyoxyethylated castor oil). Examples of oils for intra-arterial tumour treatment are disclosed in US Patent 4,578,391, which disclosure however is solely concerned with the dissolution of sparingly oil-soluble or water soluble anti-tumour drugs for infusion. Known formulations for intravenous use (Calcijex® calcitriol injection marketed by

Abbot Laboratories, as described in the Physicians Desk Reference, ibid, and also formulations disclosed in United States Patent 4,308,264) are aqueous solutions and their use in the treatment of cancers has not been reported. Moreover, their low calcitriol content would make them particularly unsuited to intra-arterial administration to the liver.

5 Further suitable carriers include multicomponent systems capable of incorporating lipophilic materials such as liposomes and microemulsions.

Tamoxifen, an oestrogen receptor antagonist, has been shown to significantly, but modestly, improve survival in human hepatoma. It has also 10 been shown that tamoxifen increases vitamin D receptor expression on breast cancer lines. We believe that tamoxifen's effect on hepatoma may be due to its effect on vitamin D receptor expression, making the tumour more sensitive to endogenous vitamin D. Tamoxifen and oestrogen or oestrogen-like compounds are therefore expected to significantly increase the effect of 15 vitamin D therapies in cancers such as hepatoma and that this will significantly increase response whilst allowing lower doses of the vitamin D compound, thus avoiding hypercalcaemia and other complications.

Accordingly in a third aspect, the present invention consists in a method of treatment in accordance with the first and second aspects of the 20 invention, the method further including administration of a compound capable of increasing vitamin D receptor expression is also administered.

The compound capable of increasing vitamin D receptor expression may be tamoxifen or other oestrogen or oestrogen-like compound.

25 The compound capable of increasing vitamin D receptor expression may be administered before, concurrently or after administration of the vitamin D compound.

In a fourth aspect the present invention consists in a composition suitable for the treatment of a tumour in the liver, the composition including a pharmaceutically effective amount of a vitamin D compound selected from

the group consisting of vitamin D, a precursor of vitamin D, or a metabolite or analogue thereof dissolved in a pharmaceutically acceptable oil.

The pharmaceutically acceptable oil is an iodised oil such as iodised poppy seed oil. The pharmaceutically acceptable oil may be a non-iodised oil, for example, poppy seed oil.

In the Figures:

Figure 1 is a graph showing the *in vitro* effect of 1,25 dihydroxyvitamin D3 on the growth of hepatoma HepG2 cells.

Figure 2 is a graph showing the *in vitro* effect of 1,25 dihydroxyvitamin D3 on the growth of human colon cancer cells LoVo treated for 10 days.

Figures 3-7 are charts showing patient serum calcium levels during treatment by the method in accordance with the present invention.

Figures 8-9 are graphs showing patient CEA levels during a course of treatment in accordance with the present invention.

Figures 10-11 are charts showing calcium levels of pigs one and two respectively showing calcium levels for intravenous and hepatic artery infusions.

Figure 12 is a graph showing the solubility of 3H vitamin D3 in both water and lipiodol.

In order that the invention be more readily understood, we provide the following non-limiting examples:

#### **Example 1 - Effect on *in vitro* growth of a human hepatoma cell line**

The effect of a range of concentrations of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> on the *in vitro* growth of the human hepatoma cell line, Hep G2, was studied. The inhibition of growth is demonstrated by a reduction in thymidine uptake by the hepatoma cells (see Figure 1). The size of inhibition reported here is astonishing, a 95% inhibition of growth was seen, although this is dose

dependent ( $10^{-11}$  M was considerably less effective). Whilst vitamin D analogues have been shown to inhibit other types of cancers, this is the first demonstration of effect in hepatoma.

We have found that the size of the inhibition effect achieved with other cancers, for example, 50-60% inhibition of growth of colorectal cancer would be regarded as a good response (see Figure 2). The effect of  $1,25$  (OH)<sub>2</sub>D<sub>3</sub> would also be even less in colorectal cancer than the analogue (EB1089) used in this comparative experiment as set out in the table below.

10 Effect of  $1,25$ (OH)<sub>2</sub>D<sub>3</sub> and EB1089 on human colon cancer cells LoVo and human hepatoma HepG2 cells. Results are % of control  $\pm$ SEM

Concentration	LoVo		HepG2	
	D <sub>3</sub>	EB1089	D <sub>3</sub>	EB1089
$10^{-7}$ M	34.2 $\pm$ 3.8	40.5 $\pm$ 10.7	7.1 $\pm$ 6.3	11.2 $\pm$ 2.7
$10^{-8}$ M	53.1 $\pm$ 5.0	51.0 $\pm$ 10.3	8.6 $\pm$ 6.3	13.1 $\pm$ 2.8
$10^{-9}$ M	74.2 $\pm$ 6.8	73.3 $\pm$ 11.7	13.8 $\pm$ 6.4	13.2 $\pm$ 2.7
$10^{-10}$ M	96.5 $\pm$ 12.9	55.3 $\pm$ 13.7	56.6 $\pm$ 6.7	49.1 $\pm$ 2.9
$10^{-11}$ M	127.4 $\pm$ 7.1	64.7 $\pm$ 12.7	105.6 $\pm$ 6.6	41.7 $\pm$ 3.6

15 LoVo cells were treated for 10 days, while HepG2 cells were treated for 5 days, with D<sub>3</sub> or EB1089.

The effect of vitamin D<sub>3</sub> analogue EB1089 on other hepatoma cell lines is given in the table below.

Cell lines	Concentration				
	10 <sup>-7</sup> M	10 <sup>-8</sup> M	10 <sup>-9</sup> M	10 <sup>-10</sup> M	10 <sup>-11</sup> M
SK-Hep	34.8 ± 5.2	63.1 ± 16.2	52.1 ± 8.8	52.1 ± 8.6	82 ± 9.2
	46.6 ± 13.0	71.3 ± 11.8	61.6 ± 12.2	61.1 ± 16.6	78.8 ± 11.5
	79.2 ± 4.4	83.1 ± 4.2	88.4 ± 4.1	91.0 ± 4.5	118.3 ± 26.4
	60.1 ± 11.7	95.6 ± 12.2	103.1 ± 12.4	103.8 ± 11.7	66.9 ± 36.9
Hep 1-6	56.1 ± 7.2	63.9 ± 7.0	78.1 ± 11.4	110.8 ± 13.8	103.4 ± 9.2
	118.9 ± 11.1	113.4 ± 5.6	106.7 ± 5.4	103.5 ± 4.5	98.1 ± 4.3
HTC	57.9 ± 7.2	63.9 ± 12.5	97.4 ± 13.8	107.8 ± 12.7	95.9 ± 13.0
	95.3 ± 17.7	86.9 ± 15.0	100.4 ± 15.4	113.0 ± 22.1	98.8 ± 15.5
NovoKoff	91.5 ± 14.5	106.0 ± 18.1	103.7 ± 13.8	116.3 ± 22.1	131.0 ± 15.9
	84.6 ± 17.0	79.0 ± 18.4	95.4 ± 18.2	94.0 ± 21.4	92.6 ± 17.6
Morris	136.0 ± 12.5	134.0 ± 13.3	117.8 ± 11.7	118.0 ± 11.9	118.0 ± 14.3
	80.1 ± 5.2	83.3 ± 4.7	79.1 ± 4.9	88.3 ± 3.9	90.8 ± 5.9
PCL	98.5 ± 4.5	101.6 ± 11.5	98.3 ± 6.5	92.5 ± 6.6	102.5 ± 10.0
	106.0 ± 9.1	105.2 ± 4.9	95.1 ± 3.3	100.1 ± 2.1	95.9 ± 2.9

(All experiments carried out in 5% charcoal treated media. All day 5. Successive lines of results for a particular cell line are the results for repeated experiment)

5

The speed of action is also very different, inhibition is measurable at 24 hours in hepatoma whereas results in colorectal cancer are modest at 5 days and usually only clear at 10 days.

The mechanism by which vitamin D<sub>3</sub> and its analogues achieve so much greater an effect in hepatoma from other cancers is, we believe, due to production of active metabolites by the hepatoma cells.

5      **Example 2 - Determination of first pass effect of 1, 25 (OH)<sub>2</sub>D<sub>3</sub>**

It is known that the principal route of excretion is in the bile, as calcitriolic acid and various other, conjugated compounds. We hypothesised that this catabolism in the liver would result in a first pass effect if 1,25(OH)<sub>2</sub>D<sub>3</sub> has been limited by high systemic concentrations and resultant hypercalcaemia.

10     Two trials were conducted with their aim being to determine whether such a first pass effect does exist, and is clinically useful. The trials were:

1.    A phase one clinical trial looking at the effects of a hepatic artery infusion of 1,25(OH)D<sub>3</sub>.
- 15    2.    A pig animal model comparing the effects of an intravenous administration of 1,25(OH)D<sub>3</sub> versus an intravenous infusion.

The methods and results of these trials are outlined below:

***Phase 1 Trial***

20     A phase one trial of the administration of a hepatic artery infusion of 1,25(OH)D<sub>3</sub> was carried out.

***Aims***

1.    To establish the safety of a hepatic artery infusion of 1,25(OH)D<sub>3</sub> in the treatment of liver cancers, in particular its effects upon serum calcium levels.
- 25    2.    To investigate the effects of such an infusion upon liver cancers by monitoring of tumour marker levels and their rate of rise.

***Subjects:***

Seven patients with either hepatoma or colorectal cancer metastases who have failed to respond to current chemotherapy regimens

The subject details are given in the following table:

NUMBER	AGE	SEX	TUMOUR	EXTRAHEPATIC DISEASE/COMPLICATIONS
1	62	F	Colorectal	Lung Metastases
2	73	M	Hepatoma	Nil
3	42	M	Colorectal	Nil
4	72	F	Colorectal	Obstructive jaundice, partially relieved by indwelling stents
5	57	M	Colorectal	Nil
6	75	M	Colorectal	Lung Metastases, obstructive jaundice relieved by indwelling stents
7	57	M	Colorectal	Obstructive jaundice, partially relieved by indwelling stents

The treatment summary is given in the following table:

Patient Number	Period 1		Period 2		Period 3		Period 4		Period 5	
	Dose (mcg/ day)	Days								
1	0.02	4	0.05	3						
2	0.02	4	0.05	3						
3	2	4	5	24	0	35	10	8	15	3
4	0.5	8	2	8	5	10				
5	2	5	5	21	0	35	10	4	15	10
6	2	4	5	23	0	25	10	4	15	3
7	2	3	5	26						

**Methods:**

Each patient given an infusion of 1,25(OH)D<sub>3</sub> via a hepatic artery catheter for either 1 week or successive 4 week periods. Regular assay of

LFTs, UECs, and calcium and phosphate levels, together with AFP or CEA levels.

Patients 1 and 2 were given first 0.2mcg/day of 1,25(OH)D<sub>3</sub> or 4 days and were then given a further 3 days of 0.5 mcg/day, both via temporary hepatic artery catheters.

Patients 3, 5 and 6 were initially given 2 mcg/day, and then four weeks of 5mcg/week. After a four week rest period in order to allow any induced hepatic enzymes to diminish they were restarted on treatment, at a dose of 10 mcg/day, this was quickly increased to 15 mcg/day.

Patient 4 was hypercalcaemic due to a paraneoplastic phenomena prior to treatment, and was therefore given lower dosages. Having started on 0.5 mcg/day this was quickly increased to 2 mcg/day and then to 5 mcg/day.

Patient 7 was commenced on the same dosage regimen as patients 3, 5 and 6 but was withdrawn from the trial prior to starting 10 mcg/day due to progression of his disease.

***Outcome Measures:***

Calcium levels - looking for the development of hypercalcaemia

CEA or AFP levels - looking for evidence of response of the tumours to treatment

UECs and LFTs - looking for unexpected effects upon hepatic and renal function.

**Results:**

Seven patients were entered in all. No patient suffered any unexpected adverse reaction or side effect to the infusion. Nor did any patient experience any derangement of hepatic or renal function.

5 Neither patients 1 nor 2 became hypercalcaemic during treatment (results not shown) with the lower doses.

In Figure 3 dotted lines denote normal range for serum calcium. Subjects 1 and 2 were treated from day 0 to 7. Subjects 3 to 7 were treated from 0 to 28.

10 Figures 3 and 4 demonstrate that at hepatic arterial infusion of up to 5 mcg/day of 1,25(OH)D<sub>3</sub> do not result in hypercalcaemia. Indeed as demonstrated in Figure 3, the calcium level of a patient with pre existing hypercalcaemia did not rise with treatment.

15 Figures 5, 6 and 7 demonstrate that doses of up to 10 mcg/day can be administered via this route without producing hypercalcaemia. These figures also show that in two out of three patients given 15 mcg/day of 1,25(OH)D<sub>3</sub>, hypercalcaemia developed.

20 Figures 8 and 9 detail the tumour marker responses of all seven patients. As can be seen in Figure 7, patient 1's marker level dramatically increased at the onset of treatment but this was followed by an equally dramatic fall in the level. Patient 2 did not experience a fall in marker level but there was a levelling off of the rate of rise with time. Patient 3 had a dramatic fall in marker level initially, but later this resumed its rise. This rise was noted to occur at the same time that extrahepatic disease was noted to 25 have developed. Figure 9 illustrates that patients 5 and 6 did not appear to have any response to treatment in terms of CEA levels rate of rise, however the rate of rise of CEA levels of patient 7 appears to have slowed somewhat perhaps indicating a response.

***Discussion and Conclusions:***

We have demonstrated that the administration of 1,25(OH)D<sub>3</sub> as an infusion via the hepatic artery is safe and without unexpected side effects. Up to 10 mcg/day of 1,25(OH)D<sub>3</sub> can be given without producing 5 hypercalcaemia. This compares with a previous trial in which 2 mcg/day of calcitriol was administered orally and resulted in hypercalcaemia in 50% of patients.

The tumour marker data is more difficult to interpret, given the fact that these patients all had very advanced hepatic disease and extrahepatic 10 disease to varying degrees, but it would appear that 4 of the 7 patients treated had at least a limited response to treatment as indicated by a fall in the rate of rise of their tumour marker levels with time.

***Example 3 - A pig animal model comparing the effects of an intravenous 15 administration of 1,25(OH)D<sub>3</sub> versus an intravenous infusion***

***Aims:***

To investigate the existence of a first pass effect on a hepatic arterials infusion of 1,25(OH)D<sub>3</sub> by comparing such an infusion's effects upon serum 20 calcium levels with the effects of an identical dosage intravenous infusion.

***Subjects:***

*Female Landrace pigs (minimal disease) of weight 15 - 50 kg.*

***Methods:***

Each animal was anaesthetised and a hepatic arterial catheter or 25 intravenous catheter was inserted, and connected to an implanted "Infusaid" pump which delivered a continuous infusion of 1,25(OH)D<sub>3</sub>. This infusion was delivered for a one or two week period, after which the animal was not treated for 4 weeks to allow any induced hepatic enzymes to diminish. The animal was then "crossed over" those whose first infusion was via the hepatic 30 artery had their pump connected to an intravenous catheter and vice versa.

Blood was taken regularly and assayed for calcium levels, LFTs and UECs.

**Results:**

To date three pigs have been entered into and completed the trial. Pigs 5 1 and 2 have both undergone intravenous and hepatic artery infusions. Pig 3 unfortunately had a reaction to halothane anaesthesia - malignant hyperpyrexia and died at its operation. No pig suffered any unexpected reaction to 1,25(OH)D<sub>3</sub> via either route, LFTs and UECs being normal in all animals throughout.

10 Figure 10 illustrates the calcium levels resulting from both intravenous and hepatic arterial infusions of 1,25(OH)D<sub>3</sub>. Clearly the intravenous route of delivery results in hypercalcaemia whereas a similar dosage when delivered via the hepatic artery does not affect calcium levels

Figures 11 demonstrates the similar results in pig 2 as for pig 1.

15 **Discussion and Conclusions:**

This trial demonstrates that an infusion of 1,25(OH)D<sub>3</sub> delivered via the hepatic artery does not produce the hypercalcaemia seen when a similar dose is delivered intravenously. This supports the existence of a first pass effect associated with hepatic arterial infusion of 1,25(OH)D<sub>3</sub>.

20

**Example 4 - Determination of solubility of vitamin D<sub>3</sub> in lipiodol**

To illustrate the solubility of vitamin D compound in lipiodol radiolabelled vitamin D<sub>3</sub> was dissolved in lipiodol at various amounts and the compared to the solubility of radiolabelled vitamin D<sub>3</sub>. The results are shown 25 in Figure 12 which demonstrates that vitamin D<sub>3</sub> is substantially more soluble in lipiodol than in an aqueous medium.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the 30 invention as broadly described. For example, the treatment method of the

present invention may be used with one or more conventional anti-cancer therapies such as radiation therapy or chemotherapy. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

**CLAIMS:**

1. A method of treating a tumour in the liver of a subject including administering to the subject a pharmaceutically effective amount of at least one vitamin D compound selected from the group consisting of vitamin D, a precursor of vitamin D, or a metabolite or analogue thereof, wherein the vitamin D compound is regionally delivered to the liver.

5 2. A method according to claim 1 wherein the vitamin D compound is delivered intraarterially or via the portal vein.

10 3. A method according to claim 2 wherein the vitamin D compound is delivered by hepatic artery infusion.

4. A method according to any one of the preceding claims wherein the vitamin D compound is delivered in a composition containing a pharmaceutically acceptable oil.

15 5. A method according to claim 4 wherein the pharmaceutically acceptable oil is an iodised oil.

6. A composition according to claim 5 wherein the iodised oil is lipiodol.

7. A method according to any one of the preceding claims wherein the tumour is a primary cancer of the liver.

8. A method according to claim 7 wherein the cancer is hepatoma.

20 9. A method according to any one of claims 1 to 7 wherein the tumour is a secondary cancer of the liver.

10. A method according to claim 9 wherein the cancer is a metastases of a cancer selected from the group consisting of colorectal cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer or renal cancer.

25 11. A method according to claim 9 wherein the secondary cancer is a sarcoma.

12. A method according to any one of the preceding claims wherein the vitamin D compound is  $1,25(\text{OH})_2\text{D}_3$ .

13. A method according to any one of the preceding claims wherein the vitamin D compound is administered with a compound capable of increasing vitamin D receptor expression.

14. A method according to claim 13 wherein the compound capable of increasing vitamin D receptor expression is an oestrogen receptor antagonist.

5 15. A method according to claim 14 wherein the compound is tamoxifen.

16. A method according to any one of the preceding claims further including one or more other anticancer treatments.

10 17. A method according claim 16 wherein the other anticancer treatment is selected from radiation therapy or chemotherapy.

18. A composition suitable for the treatment of a tumour in the liver, the composition including a pharmaceutically effective amount of a vitamin D compound selected from the group consisting of vitamin D, a precursor of vitamin D, or a metabolite or analogue thereof dissolved in a pharmaceutically acceptable oil.

15 19. A composition in accordance with claim 18 wherein the pharmaceutically acceptable oil is an iodised oil.

20. A composition according to claim 19 wherein the iodised oil is lipiodol.




Figure 1





Figure 2

Figure 3. Patient 4 Serum calcium levels



**Figure 4. Patient 7 Serum calcium levels**




Figure 5. Patient 3 Serum calcium levels





Figure 6. All Patients Serum calcium levels



**Figure 7. Patient 5 Serum calcium levels**




Figure 8. Patient 1 - 4 CEA levels





Figure 9. CEA levels of patients 5 - 7



**Figure 10. Pig one - calcium levels for intravenous and hepatic artery infusion**






Figure 11. Pig two - calcium levels for intravenous and hepatic artery infusions



**Figure 12**

100 uL Lipiodol + 100 uL Water  
Cold vitamin  $\text{D}_3$  in Lipiodol 4mM

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU98/00440

**A. CLASSIFICATION OF SUBJECT MATTER**Int Cl<sup>6</sup>: A61K 31/59

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC as above with Derwent Keywords as indicated below

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
AU: IPC as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DERWENT: Dihydroxycholecalc\* and (hepat\* or liver\* or tumor\*) and target and A61K 31/59

MEDLINE: Dihydroxycholecalc\* and (hepat\* or liver\* or tumor\*) and target

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP-A-0296800 (Yamanouchi Pharm. Co. Ltd.), 28 December 1988	1-3, 7-14, 18
Y	whole document	15-17, 19-20
X	US 4897387 A (Yamanouchi Pharm. Co) 30 January 1990	1-3, 7-14, 18
Y	whole document	15-17, 19-20
X	WO 95/01960 A (Laboratoire Theramex S.A.) 19 January 1995	1-3, 7-14, 18
Y	In partic. pages 2-3, 60, 61	15-17, 19-20

 Further documents are listed in the continuation of Box C See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
23 July 1998Date of mailing of the international search report  
30 JUL 1998Name and mailing address of the ISA/AU  
AUSTRALIAN PATENT OFFICE  
PO BOX 200  
WODEN ACT 2606  
AUSTRALIA  
Facsimile No.: (02) 6285 3929Authorized officer  
*J. A. Fernance*  
JENNIFER FERNANCE  
Telephone No.: (02) 6283 2416

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Fund. and. Clin. Pharmacol., Vol 1 No 5 1987 p. 347-355., "1,25-Dihydroxycholecalciferol induces an increase in PGE, and Forskolin-stimulated cyclic-AMP Production in T47D Human Breast Cancer cell line", de Cremoux et al -whole document.	1-20
Y	Ann. Review of Med, Vol 29 1978, p 327-42 "Osteomalacia and Disorders of Vitamin D Metabolism", Habener et al -In partic. Fig 1.	1-20
Y	Endocrinology, Vol 138 No 12 1997, p.5485-5496 "The Vitamin D Analog, KH1060 is Rapidly Degraded both in Vivo and in Vitro via Several Pathways: Principal Metabolites Generated Retain Significant Biological Activity", Dilworth et al. -whole document.	1-18
X Y	Trends in Endocrinology and metabolism, Vol 4 No 9 1993, "A Dialogue on Analogues: Newer Vitamin-D Drugs for Use in Bone Disease, Psoriasis and Cancer. -whole document.	1, 2, 3, 7-14, 18 15-17, 19-20
X Y	WO 96/40153 A (Bone Care Int. Inc) 19 December 1996 -whole document.	1-3, 7-14, 18 15-17, 19-20
X Y	MARTINDALE, the Extra Pharmacop, 13 <sup>th</sup> Ed <sup>n</sup> 1993, Pharm. Pres. Cod-liver Oil page 1038, Vitamin D Substances pages 1058-160 -In Partic their solubilities	18, 19, 20 1-17

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No.  
PCT/AU98/00440

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	96/40153	AU	63791/96	EP	831839	PL	323866
		US	5763429	US	5763428	US	5403831
		US	5602116	US	5707980	AU	53840/96
		EP	820290	FI	973868	NO	974480
		PL	322613	WO	96/31215	WO	98/29123
		AU	85422/91	BR	9106062	CA	2069084
		CN	1061220	CN	1130507	CN	1136433
		EP	503035	HU	62559	HU	9500745
		HU	211963	MX	9101224	NO	921955
		NZ	239897	ZA	9107553	WO	92/205130
		US	5488120	US	5756783	IN	173348
		PL	294706	AU	62569/96	EP	831838
		PL	323798	WO	96/40154	AU	42203/89
		EP	381750	GB	2231794	NL	8920901
		SE	9001308	WO	90/01321	WO	90/01321
		US	5104864	AU	36561/93	EP	631500
		EP	631500	WO	93/14763	DHU	9500280
EP	296800	US	4897387	US	4973721	JP	2000162
US	4897387	EP	296800	US	4973721	JP	2000162
WO	95/01960	AU	74927/94	CA	2166898	EP	707566
		NO	960099				
END OF ANNEX							